Share Price and Basic Stock Data
Last Updated: November 26, 2025, 4:33 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Astec Lifesciences Ltd operates within the agrochemical and pesticide sector, reporting a market capitalization of ₹1,391 Cr and a current share price of ₹625. The company has experienced a fluctuating revenue trajectory over recent quarters, with sales reported at ₹184 Cr in June 2022, peaking at ₹200 Cr in September 2022, and then declining to ₹127 Cr by March 2023. The most recent quarterly data shows sales of ₹111 Cr for September 2023, followed by a projected decline to ₹51 Cr in December 2023. This downward trend illustrates significant volatility in revenue generation, likely driven by market competition and operational challenges. Annual sales figures reflect a similar pattern, with ₹677 Cr in March 2022, declining to ₹628 Cr in March 2023, and further anticipated to drop to ₹458 Cr by March 2024. The trailing twelve months (TTM) revenue stands at ₹378 Cr, indicating a pressing need for strategic interventions to stabilize revenue streams.
Profitability and Efficiency Metrics
Astec Lifesciences has struggled with profitability, as evidenced by a net profit of ₹-114 Cr, resulting in a negative earnings per share (EPS) of ₹-68.71 for March 2025. The company’s operating profit margin (OPM) stood at -12%, reflecting a concerning trend of rising operational costs outpacing revenue. While the OPM was 14% in June 2022, it sharply declined to -3% by September 2023. Additionally, the interest coverage ratio (ICR) at -1.65x indicates that the company is unable to meet its interest obligations from operational earnings. The return on equity (ROE) is reported at 45.3%, which is impressive but misleading in the context of overall financial health due to the significant net losses. Efficiency metrics such as cash conversion cycle (CCC) at 237 days and inventory turnover ratio of 1.40x further underscore operational inefficiencies that need addressing to enhance profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Astec Lifesciences reveals a leverage issue, with total borrowings of ₹555 Cr against reserves of ₹215 Cr, leading to a debt-to-equity ratio of 2.36x. This high leverage raises concerns about financial stability and suggests that the company may face challenges in servicing its debt obligations. The current ratio stands at 0.93x, indicating a potential liquidity risk, as it falls below the ideal threshold of 1.0x. Furthermore, the book value per share has decreased from ₹214.00 in March 2023 to ₹119.70 in March 2025, indicating a significant erosion of shareholder equity. The return on capital employed (ROCE) has also declined to -20.22%, signifying poor capital utilization. With an enterprise value (EV) of ₹1,875.49 Cr and an EV/EBITDA ratio of -30.96, the company’s valuation is under pressure, reflecting the market’s skepticism about its future earnings potential.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Astec Lifesciences illustrates a strong promoter presence, with promoters holding 72.42% as of September 2025. However, the foreign institutional investors (FIIs) have reduced their stake to 0.00%, raising concerns regarding international investor confidence. Domestic institutional investors (DIIs) hold 4.01%, while public shareholding is at 23.57%. This distribution indicates a lack of diversified investor interest and potential vulnerability to market fluctuations. The number of shareholders has declined to 18,276, which may suggest waning investor enthusiasm. Although the high promoter holding could be seen as a vote of confidence, the absence of FIIs and the reduced public interest may reflect broader concerns about the company’s financial health and operational performance. The declining share price and net losses are likely contributing to this trend, necessitating efforts to rebuild investor trust.
Outlook, Risks, and Final Insight
Astec Lifesciences faces multiple risks that could hinder its recovery trajectory. The persistent negative profitability, as indicated by net losses and declining sales figures, poses a significant threat to operational sustainability. Additionally, high leverage could lead to financial distress if the company fails to improve cash flows and manage its debt effectively. On the upside, the strong promoter backing and potential for operational improvements present avenues for recovery. Strategic initiatives aimed at optimizing costs and enhancing sales could stabilize the business. However, without clear and decisive actions, the company risks further deterioration in investor confidence and financial stability. The outlook hinges on whether Astec can successfully navigate these challenges to restore profitability and investor sentiment, thereby positioning itself for a more favorable market reception.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Astec Lifesciences Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Epigral Ltd | 6,336 Cr. | 1,468 | 2,196/1,398 | 15.8 | 487 | 0.41 % | 24.9 % | 22.3 % | 10.0 |
| Dharmaj Crop Guard Ltd | 834 Cr. | 246 | 391/165 | 17.1 | 131 | 0.00 % | 12.0 % | 9.28 % | 10.0 |
| Bhaskar Agrochemicals Ltd | 66.6 Cr. | 128 | 149/56.6 | 11.9 | 40.0 | 0.00 % | 21.3 % | 24.7 % | 10.0 |
| Bhagiradha Chemicals & Industries Ltd | 3,227 Cr. | 249 | 365/228 | 122 | 54.9 | 0.06 % | 7.44 % | 4.91 % | 1.00 |
| Best Agrolife Ltd | 858 Cr. | 362 | 670/244 | 67.0 | 342 | 0.83 % | 12.9 % | 9.95 % | 10.0 |
| Industry Average | 11,223.60 Cr | 1,496.94 | 32.99 | 472.46 | 0.43% | 15.21% | 19.87% | 7.25 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 184 | 200 | 117 | 127 | 143 | 111 | 51 | 154 | 69 | 99 | 94 | 120 | 91 |
| Expenses | 159 | 166 | 105 | 122 | 140 | 114 | 69 | 141 | 116 | 118 | 100 | 114 | 102 |
| Operating Profit | 25 | 33 | 12 | 5 | 3 | -3 | -18 | 13 | -46 | -20 | -6 | 6 | -11 |
| OPM % | 14% | 17% | 10% | 4% | 2% | -3% | -36% | 8% | -67% | -20% | -6% | 5% | -12% |
| Other Income | 3 | 4 | 4 | 3 | 2 | 1 | 1 | 2 | 1 | 2 | 2 | 1 | 1 |
| Interest | 4 | 5 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 9 | 10 | 10 | 11 |
| Depreciation | 9 | 8 | 9 | 8 | 9 | 9 | 9 | 9 | 9 | 11 | 11 | 12 | 11 |
| Profit before tax | 15 | 25 | 1 | -6 | -11 | -18 | -32 | -1 | -62 | -39 | -25 | -16 | -33 |
| Tax % | 25% | 25% | 31% | -20% | -26% | -24% | -24% | 4% | -36% | 0% | 61% | 3% | 0% |
| Net Profit | 11 | 18 | 1 | -5 | -8 | -13 | -24 | -1 | -40 | -39 | -40 | -16 | -33 |
| EPS in Rs | 5.09 | 8.17 | 0.38 | -2.22 | -3.66 | -6.00 | -10.86 | -0.43 | -17.73 | -17.21 | -18.03 | -7.18 | -14.75 |
Last Updated: August 1, 2025, 11:55 pm
Below is a detailed analysis of the quarterly data for Astec Lifesciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 91.00 Cr.. The value appears to be declining and may need further review. It has decreased from 120.00 Cr. (Mar 2025) to 91.00 Cr., marking a decrease of 29.00 Cr..
- For Expenses, as of Jun 2025, the value is 102.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 114.00 Cr. (Mar 2025) to 102.00 Cr., marking a decrease of 12.00 Cr..
- For Operating Profit, as of Jun 2025, the value is -11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6.00 Cr. (Mar 2025) to -11.00 Cr., marking a decrease of 17.00 Cr..
- For OPM %, as of Jun 2025, the value is -12.00%. The value appears to be declining and may need further review. It has decreased from 5.00% (Mar 2025) to -12.00%, marking a decrease of 17.00%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Interest, as of Jun 2025, the value is 11.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 11.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 12.00 Cr. (Mar 2025) to 11.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -33.00 Cr.. The value appears to be declining and may need further review. It has decreased from -16.00 Cr. (Mar 2025) to -33.00 Cr., marking a decrease of 17.00 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 3.00% (Mar 2025) to 0.00%, marking a decrease of 3.00%.
- For Net Profit, as of Jun 2025, the value is -33.00 Cr.. The value appears to be declining and may need further review. It has decreased from -16.00 Cr. (Mar 2025) to -33.00 Cr., marking a decrease of 17.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -14.75. The value appears to be declining and may need further review. It has decreased from -7.18 (Mar 2025) to -14.75, marking a decrease of 7.57.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:43 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 207 | 267 | 233 | 299 | 368 | 431 | 523 | 555 | 677 | 628 | 458 | 381 | 378 |
| Expenses | 171 | 213 | 201 | 236 | 299 | 354 | 437 | 443 | 522 | 551 | 464 | 448 | 396 |
| Operating Profit | 35 | 54 | 32 | 63 | 69 | 76 | 85 | 112 | 154 | 77 | -6 | -66 | -18 |
| OPM % | 17% | 20% | 14% | 21% | 19% | 18% | 16% | 20% | 23% | 12% | -1% | -17% | -5% |
| Other Income | -0 | -16 | 4 | -8 | 12 | 11 | 12 | 8 | 10 | 13 | 6 | 6 | 4 |
| Interest | 9 | 13 | 13 | 12 | 11 | 12 | 13 | 5 | 9 | 21 | 25 | 37 | 40 |
| Depreciation | 15 | 13 | 10 | 14 | 15 | 19 | 23 | 26 | 34 | 34 | 36 | 44 | 45 |
| Profit before tax | 11 | 13 | 12 | 29 | 56 | 56 | 61 | 89 | 121 | 35 | -62 | -141 | -98 |
| Tax % | 22% | -17% | 59% | 33% | 37% | 36% | 23% | 27% | 26% | 27% | -24% | -4% | |
| Net Profit | 9 | 15 | 5 | 19 | 35 | 36 | 48 | 65 | 90 | 26 | -47 | -135 | -114 |
| EPS in Rs | 4.09 | 6.66 | 2.24 | 8.57 | 15.65 | 16.03 | 21.21 | 29.04 | 40.12 | 11.41 | -20.95 | -60.16 | -50.92 |
| Dividend Payout % | 21% | 16% | 0% | 15% | 8% | 8% | 6% | 5% | 3% | 12% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 66.67% | -66.67% | 280.00% | 84.21% | 2.86% | 33.33% | 35.42% | 38.46% | -71.11% | -280.77% | -187.23% |
| Change in YoY Net Profit Growth (%) | 0.00% | -133.33% | 346.67% | -195.79% | -81.35% | 30.48% | 2.08% | 3.04% | -109.57% | -209.66% | 93.54% |
Astec Lifesciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -6% |
| 3 Years: | -17% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -63% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | -7% |
| 3 Years: | -23% |
| 1 Year: | -29% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 0% |
| 3 Years: | -14% |
| Last Year: | -45% |
Last Updated: September 4, 2025, 11:55 pm
Balance Sheet
Last Updated: July 25, 2025, 3:34 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 19 | 19 | 19 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| Reserves | 95 | 116 | 99 | 119 | 150 | 183 | 227 | 290 | 377 | 400 | 350 | 215 |
| Borrowings | 83 | 93 | 127 | 127 | 125 | 176 | 99 | 187 | 279 | 341 | 494 | 555 |
| Other Liabilities | 88 | 133 | 85 | 69 | 119 | 83 | 226 | 181 | 221 | 219 | 112 | 92 |
| Total Liabilities | 284 | 362 | 330 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 975 | 881 |
| Fixed Assets | 132 | 133 | 95 | 103 | 115 | 167 | 194 | 213 | 340 | 318 | 386 | 499 |
| CWIP | 6 | 12 | 20 | 8 | 42 | 19 | 24 | 116 | 23 | 127 | 165 | 21 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 146 | 216 | 215 | 223 | 256 | 275 | 354 | 349 | 534 | 534 | 424 | 361 |
| Total Assets | 284 | 362 | 330 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 975 | 881 |
Below is a detailed analysis of the balance sheet data for Astec Lifesciences Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 20.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 20.00 Cr..
- For Reserves, as of Mar 2025, the value is 215.00 Cr.. The value appears to be declining and may need further review. It has decreased from 350.00 Cr. (Mar 2024) to 215.00 Cr., marking a decrease of 135.00 Cr..
- For Borrowings, as of Mar 2025, the value is 555.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 494.00 Cr. (Mar 2024) to 555.00 Cr., marking an increase of 61.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 92.00 Cr.. The value appears to be improving (decreasing). It has decreased from 112.00 Cr. (Mar 2024) to 92.00 Cr., marking a decrease of 20.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 881.00 Cr.. The value appears to be improving (decreasing). It has decreased from 975.00 Cr. (Mar 2024) to 881.00 Cr., marking a decrease of 94.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 499.00 Cr.. The value appears strong and on an upward trend. It has increased from 386.00 Cr. (Mar 2024) to 499.00 Cr., marking an increase of 113.00 Cr..
- For CWIP, as of Mar 2025, the value is 21.00 Cr.. The value appears to be declining and may need further review. It has decreased from 165.00 Cr. (Mar 2024) to 21.00 Cr., marking a decrease of 144.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 361.00 Cr.. The value appears to be declining and may need further review. It has decreased from 424.00 Cr. (Mar 2024) to 361.00 Cr., marking a decrease of 63.00 Cr..
- For Total Assets, as of Mar 2025, the value is 881.00 Cr.. The value appears to be declining and may need further review. It has decreased from 975.00 Cr. (Mar 2024) to 881.00 Cr., marking a decrease of 94.00 Cr..
However, the Borrowings (555.00 Cr.) are higher than the Reserves (215.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -48.00 | -39.00 | -95.00 | -64.00 | -56.00 | -100.00 | -14.00 | -75.00 | -125.00 | -264.00 | -500.00 | -621.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 91 | 142 | 126 | 135 | 122 | 103 | 112 | 123 | 148 | 90 | 135 | 141 |
| Inventory Days | 192 | 147 | 177 | 133 | 122 | 121 | 131 | 113 | 176 | 268 | 224 | 196 |
| Days Payable | 114 | 179 | 169 | 116 | 155 | 83 | 218 | 137 | 179 | 161 | 102 | 100 |
| Cash Conversion Cycle | 168 | 109 | 134 | 152 | 89 | 142 | 25 | 100 | 145 | 197 | 256 | 237 |
| Working Capital Days | 23 | 19 | -28 | 1 | -8 | -2 | 8 | 4 | 12 | -17 | -1 | -26 |
| ROCE % | 11% | 20% | 12% | 20% | 22% | 20% | 20% | 22% | 22% | 8% | -4% | -13% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 468,589 | 0.17 | 62.02 | 468,589 | 2025-04-22 17:25:41 | 0% |
| ICICI Prudential Multicap Fund | 457,669 | 0.69 | 60.58 | 457,669 | 2025-04-22 17:25:41 | 0% |
| ICICI Prudential Smallcap Fund | 452,546 | 0.99 | 59.9 | 452,546 | 2025-04-22 17:25:41 | 0% |
| Nippon India Multi Cap Fund | 257,718 | 0.16 | 34.11 | 257,718 | 2025-04-22 17:25:41 | 0% |
| ICICI Prudential Commodities Fund | 112,360 | 1.12 | 14.87 | 112,360 | 2025-04-22 17:25:42 | 0% |
| ICICI Prudential MidCap Fund | 15,844 | 0.05 | 2.1 | 15,844 | 2025-04-22 17:25:42 | 0% |
| ITI Value Fund | 11,923 | 1.13 | 1.58 | 11,923 | 2025-04-22 17:25:42 | 0% |
| ITI Pharma and Healthcare Fund | 11,754 | 1.15 | 1.56 | 11,754 | 2025-04-22 17:25:42 | 0% |
| Motilal Oswal Nifty Microcap 250 Index Fund | 5,371 | 0.18 | 0.71 | 5,371 | 2025-04-22 17:25:42 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -68.71 | -23.93 | 13.04 | 45.87 | 33.23 |
| Diluted EPS (Rs.) | -68.71 | -23.93 | 13.04 | 45.85 | 33.21 |
| Cash EPS (Rs.) | -46.40 | -5.42 | 30.22 | 63.39 | 46.32 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 119.70 | 188.44 | 214.00 | 202.40 | 157.91 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 119.70 | 188.44 | 214.00 | 202.40 | 157.91 |
| Revenue From Operations / Share (Rs.) | 194.43 | 233.66 | 320.40 | 345.23 | 283.28 |
| PBDIT / Share (Rs.) | -30.89 | -0.13 | 45.56 | 83.96 | 61.00 |
| PBIT / Share (Rs.) | -53.18 | -18.62 | 28.39 | 66.43 | 47.90 |
| PBT / Share (Rs.) | -71.89 | -31.49 | 17.82 | 61.81 | 45.47 |
| Net Profit / Share (Rs.) | -68.69 | -23.91 | 13.05 | 45.86 | 33.22 |
| NP After MI And SOA / Share (Rs.) | -68.71 | -23.93 | 13.04 | 45.85 | 33.21 |
| PBDIT Margin (%) | -15.88 | -0.05 | 14.21 | 24.31 | 21.53 |
| PBIT Margin (%) | -27.35 | -7.97 | 8.86 | 19.24 | 16.90 |
| PBT Margin (%) | -36.97 | -13.47 | 5.56 | 17.90 | 16.05 |
| Net Profit Margin (%) | -35.32 | -10.23 | 4.07 | 13.28 | 11.72 |
| NP After MI And SOA Margin (%) | -35.33 | -10.24 | 4.06 | 13.28 | 11.72 |
| Return on Networth / Equity (%) | -57.40 | -12.70 | 6.09 | 22.66 | 21.03 |
| Return on Capital Employeed (%) | -20.22 | -6.32 | 12.28 | 32.05 | 26.40 |
| Return On Assets (%) | -15.28 | -4.81 | 2.61 | 10.02 | 9.60 |
| Long Term Debt / Equity (X) | 1.19 | 0.53 | 0.02 | 0.00 | 0.12 |
| Total Debt / Equity (X) | 2.36 | 1.34 | 0.81 | 0.70 | 0.60 |
| Asset Turnover Ratio (%) | 0.41 | 0.46 | 0.66 | 0.85 | 0.88 |
| Current Ratio (X) | 0.93 | 1.00 | 0.94 | 1.05 | 1.03 |
| Quick Ratio (X) | 0.49 | 0.51 | 0.38 | 0.67 | 0.69 |
| Inventory Turnover Ratio (X) | 1.40 | 1.30 | 1.91 | 3.04 | 3.03 |
| Dividend Payout Ratio (NP) (%) | 0.00 | -6.26 | 11.50 | 3.26 | 4.51 |
| Dividend Payout Ratio (CP) (%) | 0.00 | -27.54 | 4.96 | 2.36 | 3.23 |
| Earning Retention Ratio (%) | 0.00 | 106.26 | 88.50 | 96.74 | 95.49 |
| Cash Earning Retention Ratio (%) | 0.00 | 127.54 | 95.04 | 97.64 | 96.77 |
| Interest Coverage Ratio (X) | -1.65 | -0.01 | 4.31 | 18.17 | 25.15 |
| Interest Coverage Ratio (Post Tax) (X) | -2.67 | -0.85 | 2.24 | 10.92 | 14.69 |
| Enterprise Value (Cr.) | 1875.49 | 2574.29 | 3049.60 | 3711.79 | 2144.94 |
| EV / Net Operating Revenue (X) | 4.92 | 5.62 | 4.85 | 5.49 | 3.87 |
| EV / EBITDA (X) | -30.96 | -9580.53 | 34.14 | 22.56 | 17.95 |
| MarketCap / Net Operating Revenue (X) | 3.47 | 4.55 | 4.31 | 5.08 | 3.53 |
| Retention Ratios (%) | 0.00 | 106.26 | 88.49 | 96.73 | 95.48 |
| Price / BV (X) | 5.64 | 5.64 | 6.46 | 8.66 | 6.34 |
| Price / Net Operating Revenue (X) | 3.47 | 4.55 | 4.31 | 5.08 | 3.53 |
| EarningsYield | -0.10 | -0.02 | 0.01 | 0.02 | 0.03 |
After reviewing the key financial ratios for Astec Lifesciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -68.71. This value is below the healthy minimum of 5. It has decreased from -23.93 (Mar 24) to -68.71, marking a decrease of 44.78.
- For Diluted EPS (Rs.), as of Mar 25, the value is -68.71. This value is below the healthy minimum of 5. It has decreased from -23.93 (Mar 24) to -68.71, marking a decrease of 44.78.
- For Cash EPS (Rs.), as of Mar 25, the value is -46.40. This value is below the healthy minimum of 3. It has decreased from -5.42 (Mar 24) to -46.40, marking a decrease of 40.98.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 119.70. It has decreased from 188.44 (Mar 24) to 119.70, marking a decrease of 68.74.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 119.70. It has decreased from 188.44 (Mar 24) to 119.70, marking a decrease of 68.74.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 194.43. It has decreased from 233.66 (Mar 24) to 194.43, marking a decrease of 39.23.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -30.89. This value is below the healthy minimum of 2. It has decreased from -0.13 (Mar 24) to -30.89, marking a decrease of 30.76.
- For PBIT / Share (Rs.), as of Mar 25, the value is -53.18. This value is below the healthy minimum of 0. It has decreased from -18.62 (Mar 24) to -53.18, marking a decrease of 34.56.
- For PBT / Share (Rs.), as of Mar 25, the value is -71.89. This value is below the healthy minimum of 0. It has decreased from -31.49 (Mar 24) to -71.89, marking a decrease of 40.40.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -68.69. This value is below the healthy minimum of 2. It has decreased from -23.91 (Mar 24) to -68.69, marking a decrease of 44.78.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -68.71. This value is below the healthy minimum of 2. It has decreased from -23.93 (Mar 24) to -68.71, marking a decrease of 44.78.
- For PBDIT Margin (%), as of Mar 25, the value is -15.88. This value is below the healthy minimum of 10. It has decreased from -0.05 (Mar 24) to -15.88, marking a decrease of 15.83.
- For PBIT Margin (%), as of Mar 25, the value is -27.35. This value is below the healthy minimum of 10. It has decreased from -7.97 (Mar 24) to -27.35, marking a decrease of 19.38.
- For PBT Margin (%), as of Mar 25, the value is -36.97. This value is below the healthy minimum of 10. It has decreased from -13.47 (Mar 24) to -36.97, marking a decrease of 23.50.
- For Net Profit Margin (%), as of Mar 25, the value is -35.32. This value is below the healthy minimum of 5. It has decreased from -10.23 (Mar 24) to -35.32, marking a decrease of 25.09.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -35.33. This value is below the healthy minimum of 8. It has decreased from -10.24 (Mar 24) to -35.33, marking a decrease of 25.09.
- For Return on Networth / Equity (%), as of Mar 25, the value is -57.40. This value is below the healthy minimum of 15. It has decreased from -12.70 (Mar 24) to -57.40, marking a decrease of 44.70.
- For Return on Capital Employeed (%), as of Mar 25, the value is -20.22. This value is below the healthy minimum of 10. It has decreased from -6.32 (Mar 24) to -20.22, marking a decrease of 13.90.
- For Return On Assets (%), as of Mar 25, the value is -15.28. This value is below the healthy minimum of 5. It has decreased from -4.81 (Mar 24) to -15.28, marking a decrease of 10.47.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 1.19. This value exceeds the healthy maximum of 1. It has increased from 0.53 (Mar 24) to 1.19, marking an increase of 0.66.
- For Total Debt / Equity (X), as of Mar 25, the value is 2.36. This value exceeds the healthy maximum of 1. It has increased from 1.34 (Mar 24) to 2.36, marking an increase of 1.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.41. It has decreased from 0.46 (Mar 24) to 0.41, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 0.93. This value is below the healthy minimum of 1.5. It has decreased from 1.00 (Mar 24) to 0.93, marking a decrease of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 0.49. This value is below the healthy minimum of 1. It has decreased from 0.51 (Mar 24) to 0.49, marking a decrease of 0.02.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.40. This value is below the healthy minimum of 4. It has increased from 1.30 (Mar 24) to 1.40, marking an increase of 0.10.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has increased from -6.26 (Mar 24) to 0.00, marking an increase of 6.26.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has increased from -27.54 (Mar 24) to 0.00, marking an increase of 27.54.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 106.26 (Mar 24) to 0.00, marking a decrease of 106.26.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 127.54 (Mar 24) to 0.00, marking a decrease of 127.54.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -1.65. This value is below the healthy minimum of 3. It has decreased from -0.01 (Mar 24) to -1.65, marking a decrease of 1.64.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -2.67. This value is below the healthy minimum of 3. It has decreased from -0.85 (Mar 24) to -2.67, marking a decrease of 1.82.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,875.49. It has decreased from 2,574.29 (Mar 24) to 1,875.49, marking a decrease of 698.80.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.92. This value exceeds the healthy maximum of 3. It has decreased from 5.62 (Mar 24) to 4.92, marking a decrease of 0.70.
- For EV / EBITDA (X), as of Mar 25, the value is -30.96. This value is below the healthy minimum of 5. It has increased from -9,580.53 (Mar 24) to -30.96, marking an increase of 9,549.57.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.47. This value exceeds the healthy maximum of 3. It has decreased from 4.55 (Mar 24) to 3.47, marking a decrease of 1.08.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 106.26 (Mar 24) to 0.00, marking a decrease of 106.26.
- For Price / BV (X), as of Mar 25, the value is 5.64. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 24) which recorded 5.64.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.47. This value exceeds the healthy maximum of 3. It has decreased from 4.55 (Mar 24) to 3.47, marking a decrease of 1.08.
- For EarningsYield, as of Mar 25, the value is -0.10. This value is below the healthy minimum of 5. It has decreased from -0.02 (Mar 24) to -0.10, marking a decrease of 0.08.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Astec Lifesciences Ltd:
- Net Profit Margin: -35.32%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -20.22% (Industry Average ROCE: 15.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -57.4% (Industry Average ROE: 19.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -2.67
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.49
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 32.99)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 2.36
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -35.32%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Agro Chemicals/Pesticides | Godrej One, 3rd Floor, Pirojshanagar, Mumbai Maharashtra 400079 | astecinfo@godrejastec.com http://www.godrejastec.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Nadir B Godrej | Chairman |
| Mr. Burjis N Godrej | Managing Director |
| Mr. Balram Singh Yadav | Non Executive Director |
| Mr. Ashok V Hiremath | Non Executive Director |
| Dr. Ganapati Yadav | Independent Director |
| Mr. R R Govindan | Independent Director |
| Mr. Nandkumar Dhekne | Independent Director |
| Ms. Anjali Gupte | Independent Director |
FAQ
What is the intrinsic value of Astec Lifesciences Ltd?
Astec Lifesciences Ltd's intrinsic value (as of 27 November 2025) is 1031.32 which is 15.36% higher the current market price of 894.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 1,991 Cr. market cap, FY2025-2026 high/low of 1,254/607, reserves of ₹215 Cr, and liabilities of 881 Cr.
What is the Market Cap of Astec Lifesciences Ltd?
The Market Cap of Astec Lifesciences Ltd is 1,991 Cr..
What is the current Stock Price of Astec Lifesciences Ltd as on 27 November 2025?
The current stock price of Astec Lifesciences Ltd as on 27 November 2025 is 894.
What is the High / Low of Astec Lifesciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Astec Lifesciences Ltd stocks is 1,254/607.
What is the Stock P/E of Astec Lifesciences Ltd?
The Stock P/E of Astec Lifesciences Ltd is .
What is the Book Value of Astec Lifesciences Ltd?
The Book Value of Astec Lifesciences Ltd is 186.
What is the Dividend Yield of Astec Lifesciences Ltd?
The Dividend Yield of Astec Lifesciences Ltd is 0.00 %.
What is the ROCE of Astec Lifesciences Ltd?
The ROCE of Astec Lifesciences Ltd is 12.9 %.
What is the ROE of Astec Lifesciences Ltd?
The ROE of Astec Lifesciences Ltd is 45.3 %.
What is the Face Value of Astec Lifesciences Ltd?
The Face Value of Astec Lifesciences Ltd is 10.0.